ImageneBio (NASDAQ:IMA) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS

ImageneBio (NASDAQ:IMA) posted its quarterly earnings results on Monday. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.08), FiscalAI reports.

ImageneBio Price Performance

Shares of ImageneBio stock opened at $4.12 on Tuesday. ImageneBio has a one year low of $3.88 and a one year high of $8.84. The business’s 50 day simple moving average is $4.50 and its two-hundred day simple moving average is $5.56. The stock has a market capitalization of $46.76 million, a P/E ratio of -0.90 and a beta of 0.83.

Institutional Investors Weigh In On ImageneBio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Trails Edge Capital Partners LP acquired a new position in shares of ImageneBio in the 2nd quarter valued at $1,663,824. Blue Owl Capital Holdings LP acquired a new position in shares of ImageneBio in the second quarter worth about $5,414,000. Cable Car Capital LP purchased a new position in ImageneBio during the second quarter worth approximately $4,611,000. BlackRock Inc. acquired a new stake in shares of ImageneBio in the second quarter valued at about $797,000. Finally, Stonepine Capital Management LLC acquired a new position in ImageneBio in the 2nd quarter valued at $539,044,000. Hedge funds and other institutional investors own 75.00% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on IMA shares. HC Wainwright started coverage on ImageneBio in a research note on Friday, August 21st. They set a “buy” rating and a $28.00 price objective on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of ImageneBio in a research report on Friday, September 25th. One research analyst has rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Reduce” and an average target price of $28.00.

ImageneBio Company Profile

ImageneBio, Inc is a biotechnology company focused on advancing precision oncology through blood-based molecular testing and data analysis. The company develops technologies designed to help identify and monitor cancer-related genomic signals using liquid biopsy samples.

Its platform is intended to support the detection and tracking of tumor biomarkers, potentially helping clinicians assess treatment response, identify disease progression, and guide more personalized cancer-care decisions.